Cirrhosis of the Liver - Comprehensive Long Question Answer

1. DEFINITION

"Cirrhosis refers to the diffuse transformation of the liver into regenerative parenchymal nodules surrounded by fibrous bands."

• Robbins & Kumar Basic Pathology

2. CLASSIFICATION OF CIRRHOSIS

A. Morphological Classification

B. Aetiological Classification

3. AETIOPATHOGENESIS OF CIRRHOSIS (General)

Step 1 - Repeated/Sustained Hepatocellular Injury

Step 2 - Stellate Cell Activation and Fibrogenesis

• Damaged hepatocytes and Kupffer cells release TGF-β, TNF-α, IL-1, and platelet-derived growth factor (PDGF).
• These cytokines activate hepatic stellate cells (Ito cells) in the space of Disse.
• Activated stellate cells transform into myofibroblast-like cells and produce large amounts of type I and III collagen, fibronectin, and other extracellular matrix (ECM) components.
• Result: progressive perisinusoidal fibrosis leading to "capillarization of sinusoids" (loss of fenestrations in the sinusoidal endothelium), which impairs exchange between blood and hepatocytes.

Step 3 - Regeneration and Nodule Formation

• Surviving hepatocytes undergo regenerative hyperplasia, forming nodules without the normal lobular architecture.
• These nodules are enclosed by fibrous septa that link portal tracts to central veins (bridging fibrosis), disrupting normal lobular architecture.

Step 4 - Vascular Distortion

• Perivenular fibrosis and fibrous obliteration of terminal hepatic venules (phlebosclerosis)
• Veno-occlusive lesions → sinusoidal hypertension → portal hypertension
• Portosystemic shunting: blood bypasses functioning hepatocytes

4. AETIOPATHOGENESIS OF ALCOHOLIC CIRRHOSIS

4.1 Epidemiology

• Alcohol accounts for 48% of cirrhosis worldwide, causing 1.16 million deaths annually
• Only 10-20% of heavy drinkers develop cirrhosis - other cofactors are important
• Threshold: 80 g/day of ethanol (80-proof liquor); cirrhosis typically takes 10-20 years to develop

4.2 Risk Factors for Progression

4.3 Mechanisms of Alcohol-Induced Hepatocyte Injury

Ethanol → (ADH1) → Acetaldehyde → (ALDH) → Acetate
Ethanol → (CYP2E1, induced by chronic drinking) → Acetaldehyde + ROS

1. Altered redox state (NADH/NAD+ ratio):
   • Ethanol oxidation converts NAD+ to NADH
   • High NADH/NAD+ inhibits beta-oxidation of fatty acids and gluconeogenesis
   • Promotes fatty acid synthesis → hepatic steatosis
2. Acetaldehyde toxicity:
   • Induces lipid peroxidation
   • Forms acetaldehyde-protein adducts → cytoskeletal and membrane disruption
   • May generate neoantigens triggering immune injury
3. CYP2E1-induced oxidative stress:
   • Induction by chronic alcohol consumption increases reactive oxygen species (ROS)
   • ROS damage cellular proteins, membranes, and mitochondria
   • May promote hepatocyte apoptosis
4. Impaired methionine metabolism:
   • Alcohol decreases hepatic glutathione levels → sensitisation to oxidative injury
   • Homocysteine production → endoplasmic reticulum (ER) stress
5. Gut-derived endotoxaemia (LPS/PAMPs):
   • Alcohol increases gut permeability
   • Bacterial lipopolysaccharide (LPS) enters portal circulation
   • Activates Kupffer cells via TLR4/CD14
   • Triggers NLRP3 inflammasome, releasing IL-1β and caspase-1
   • Sustained Kupffer cell activation → chronic hepatic inflammation
6. Mitochondrial dysfunction:
   • Impaired beta-oxidation → fat accumulation
   • Reduced oxidative phosphorylation → cellular energy deficiency

Progression of alcohol-associated liver disease: Steatosis → Steatohepatitis → Cirrhosis (Robbins, Cotran & Kumar)

5. MORPHOLOGY OF ALCOHOLIC CIRRHOSIS

5.1 Gross Morphology

• Liver enlarged (up to 4-6 kg), soft, yellow, greasy
• Changes begin in centrilobular zone 3 and extend outward
• Reversible with abstinence

• Liver may be enlarged or normal in size
• Yellow-tan cut surface; may show irregular nodularity beginning

• Liver is shrunken and firm in end-stage disease
• Surface is diffusely nodular (bumpy texture); normal smooth capsule replaced by irregular surface with depressed scarring and bulging nodules
• Micronodular pattern (Laennec's cirrhosis) initially: nodules <3 mm, uniform in size; with abstinence may evolve into a macronodular or mixed pattern
• Cut surface shows alternating tan-yellow regenerative nodules separated by grey-white fibrous septa

5.2 Microscopic Morphology

• Lipid droplets begin as small (microvesicular) then coalesce into large (macrovesicular) droplets
• Macrovesicular steatosis predominates: fat displaces nucleus to periphery
• Most prominent around central vein (zone 3)

• Fibrous septa interconnect portal tracts and central veins (bridging fibrosis)
• Parenchyma replaced by regenerative nodules with disrupted lobular architecture
• Perivenular fibrosis → phlebosclerosis (fibrous obliteration of terminal hepatic venules)
• Loss of bile ductules in fibrous septa (ductular reaction)
• Variable steatosis and residual inflammation

Alcohol-associated cirrhosis: Micronodular pattern (smaller nodules at left) merging with macronodular areas (larger nodule at right). Dense blue fibrous bands separate regenerative nodules (Masson trichrome stain). - Robbins, Cotran & Kumar

Regression: With prolonged abstinence, fibrous septa become thin and incomplete. Most scars can regress (Fig. 14.6B from Robbins Basic Pathology), but complete regression of cirrhosis is rare.

6. CLINICAL FINDINGS

6.1 Compensated Cirrhosis (~40% asymptomatic)

• Fatigue, weakness, anorexia, weight loss
• Hepatomegaly (early); shrunken liver (late)
• Mild elevation of liver enzymes

6.2 Specific Signs in Alcoholic Cirrhosis

• Hepatomegaly (tender in active hepatitis)
• Jaundice (hyperbilirubinemia)
• Dupuytren's contracture (palmar fibromatosis - classic in alcoholics)

• Spider angiomata (arterial spider naevi)
• Palmar erythema
• Gynecomastia, testicular atrophy, loss of libido (males)
• Amenorrhoea (females)
• Rhinophyma (bulbous red nose)
• Jaundice and pruritus (from cholestasis; bile salt accumulation)

• Ascites
• Caput medusae (dilated periumbilical veins)
• Splenomegaly
• Haemorrhoids

• Hepatic encephalopathy (asterixis/flapping tremor, confusion, coma)
• Peripheral neuropathy (from vitamin B1/B12 deficiency)

• Malnutrition and sarcopenia
• Ecchymoses/bleeding tendency (coagulopathy from decreased clotting factor synthesis)
• Oedema (hypoalbuminaemia)
• Parotid enlargement

6.3 Laboratory Findings

7. COMPLICATIONS

Major clinical consequences of portal hypertension in cirrhosis - Robbins Basic Pathology

A. Portal Hypertension

• Mechanism: increased sinusoidal resistance (fibrosis + stellate cell contraction) + increased portal blood flow (splanchnic vasodilation)
• Leads to all downstream complications

B. Oesophageal and Gastric Varices

• Develop in ~40% of patients with advanced cirrhosis
• Portosystemic collaterals at oesophago-gastric junction
• Variceal bleeding: massive haematemesis; frequently fatal especially with coagulopathy

C. Ascites

• ~85% of ascites cases are due to portal hypertension from cirrhosis
• Transudate: protein <3 g/dL; serum-to-ascites albumin gradient (SAAG) ≥1.1 g/dL
• Mechanism: portal hypertension + hypoalbuminaemia + renal sodium/water retention (RAAS activation)
• Risk: Spontaneous Bacterial Peritonitis (SBP)

D. Hepatic Encephalopathy

• Accumulation of neurotoxins (ammonia, manganese, false neurotransmitters) due to portosystemic shunting and reduced hepatocyte function
• Clinical stages: from subtle personality changes → confusion → stupor → coma
• Precipitants: GI bleeding, infection, sedatives, hypokalemia, constipation

E. Hepatorenal Syndrome (HRS)

• Functional renal failure without intrinsic renal disease
• Mechanism: liver failure → vasodilator production (NO) → splanchnic vasodilation → decreased renal perfusion → renal vasoconstriction via renin-angiotensin and renal sympathetic activation
• Reversible if liver function restored (e.g., liver transplantation)

F. Splenomegaly and Hypersplenism

• Congestive splenomegaly from portal hypertension
• Spleen may reach 1000 g
• Hypersplenism → thrombocytopenia, anaemia, leukopenia (pancytopenia)

G. Coagulopathy

• Decreased synthesis of clotting factors (I, II, V, VII, IX, X) by failing hepatocytes
• Risk of spontaneous bleeding

H. Hepatocellular Carcinoma (HCC)

• Annual risk: 1-6% in alcoholic cirrhosis
• Cirrhosis of any cause is the single most important risk factor for HCC
• Most chronic liver diseases predispose to HCC

I. Portopulmonary Hypertension

• Pulmonary vasoconstriction due to vasoactive substances bypassing liver

J. Acute-on-Chronic Liver Failure

• Sudden decompensation triggered by: infection, GI bleed, superimposed acute hepatitis, drugs

8. PROGNOSIS

• 5-year survival in abstainers (free of jaundice, ascites, hematemesis): ~90%
• 5-year survival with continued drinking: 50-60%
• Common causes of death:
  1. Hepatic coma (liver failure)
  2. Massive GI haemorrhage (variceal bleeding)
  3. Intercurrent infection (sepsis, SBP)
  4. Hepatorenal syndrome
  5. Hepatocellular carcinoma

Pathology of Regenerative and Neoplastic Hepatocellular Nodules

OVERVIEW: THE NODULAR SPECTRUM

Cirrhotic/Regenerative Nodule
         ↓
    Large Cell Change
    Small Cell Change
         ↓
  Low-Grade Dysplastic Nodule
         ↓
  High-Grade Dysplastic Nodule (+ "nodule-in-nodule")
         ↓
  Early / Well-differentiated HCC
         ↓
  Overt / Advanced HCC

• Focal Nodular Hyperplasia (FNH)
• Hepatocellular Adenoma

I. REGENERATIVE NODULES

A. Cirrhotic (Regenerative) Nodules

• Microscopically: nodules composed of hepatocytes with preserved lobular architecture (though simplified); cells are normal in size and cytology
• Surrounded by fibrous bands (portal-to-portal or portal-to-central bridging fibrosis)
• No cytologic atypia
• Micronodular (<3 mm, seen in alcoholic/metabolic disease) or macronodular (>3 mm, seen in post-viral disease)

B. Large Cell Change (Large Cell Dysplasia)

• Hepatocytes that are enlarged with large, often atypical nuclei (nuclear enlargement proportional to cytoplasmic enlargement)
• Scattered throughout the lobule; do not form discrete nodules
• Not a truly dysplastic lesion in a strict sense - may represent a senescent, stress-induced change
• Associated with HCV infection and cirrhosis

(A) Large cell change: enlarged hepatocytes with large atypical nuclei. (B) Small cell change: high nuclear-to-cytoplasmic ratio with thickened cell plates. - Robbins, Cotran & Kumar

C. Small Cell Change

• Hepatocytes are smaller than normal with a high nuclear-to-cytoplasmic (N:C) ratio
• Cells grow in thickened plates (2-3 cell plates thick vs normal 1-2)
• Clusters may form and are clonal
• Most closely associated with early HCC and high-grade dysplastic nodules

D. Focal Nodular Hyperplasia (FNH)

• Well-demarcated but poorly encapsulated nodule, may be several centimeters in diameter
• Central stellate (star-shaped) fibrous scar - pathognomonic feature - from which fibrous septa radiate to periphery
• Normal background liver

• Central scar contains large anomalous (thick-walled) arteries and ductular reactions along the fibrous septa
• Hepatocytes appear normal histologically
• No encapsulation; no portal tracts in nodular parenchyma
• No cytologic atypia, no malignant potential

II. HEPATOCELLULAR ADENOMA (Benign Neoplasm)

• Reproductive-age women (historically linked to oral contraceptive pills, now more linked to obesity and metabolic syndrome)
• Anabolic steroid use in men
• Glycogen storage disease

• Usually solitary, well-demarcated mass; no fibrous capsule (or thin capsule)
• May have areas of haemorrhage or necrosis (particularly when large, >5 cm)
• No central scar (distinguishes from FNH)
• Cut surface: pale-tan to yellow

• Sheets and cords of hepatocytes resembling normal hepatocytes
• Arterial vascular supply (unpaired arteries without portal tracts) - key diagnostic feature
• No portal tracts within the tumour
• No bile ducts within the tumour
• Variable degree of cytologic atypia depending on subtype; β-catenin-activated type shows most atypia

• Haemorrhage and rupture (especially >5 cm) → life-threatening intra-abdominal bleeding
• Malignant transformation to HCC (especially β-catenin-activated subtype)

III. DYSPLASTIC NODULES (Premalignant)

A. Low-Grade Dysplastic Nodule (LGDN)

• Slightly larger than surrounding cirrhotic nodules
• Mild cytologic atypia: slightly increased N:C ratio, mild nuclear irregularity
• Architecture largely preserved; no increased cell density
• Clonal, but few molecular aberrations
• No increased arterialization
• Low but not zero risk of progression

B. High-Grade Dysplastic Nodule (HGDN)

• Distinctly larger than surrounding cirrhotic nodules
• Significant cytologic atypia: prominent nuclear irregularity, increased N:C ratio, mitotic figures
• Increased cell density; thickened plates
• Small cell change prominent
• Clonal aberrations associated with overt HCC (TERT promoter mutations, etc.)
• Increased unpaired arteries (arterial neovascularisation begins)
• "Nodule-in-nodule" appearance: small foci of overt HCC visible within the dysplastic nodule

Hepatitis C cirrhosis with a distinctively large dysplastic nodule (arrows). Nodule-in-nodule growth indicates early HCC (A, gross; B, histology). - Robbins, Cotran & Kumar

IV. HEPATOCELLULAR CARCINOMA (HCC)

Epidemiology

• ~5-5.4% of all cancers worldwide

• 85% of cases occur in Asia (SE China, Korea, Taiwan) and sub-Saharan Africa (endemic HBV)

• Male predominance: 3:1 (low-incidence areas) to 8:1 (high-incidence areas)
• Rising in Western countries due to HCV and MASLD

Risk Factors / Aetiology

Pathogenesis / Molecular Biology

• Chronic liver injury → hepatocyte regeneration → acquisition of driver mutations
• Viruses and toxins are not directly oncogenic; rather, inflammation drives proliferation and mutagenesis
• Key driver mutations in HCC:
  • TERT promoter mutations (50-60% of tumours) - upregulate telomerase, prevent replicative senescence
  • β-catenin (CTNNB1) activating mutations (~40%) - activate Wnt signalling, promote proliferation
  • TP53 inactivating mutations (up to 60%) - loss of cell cycle arrest/apoptosis
  • CDKN2A (p16) loss, PI3K/AKT/mTOR pathway activation
• In noncirrhotic liver, HCC can arise from malignant transformation of hepatocellular adenoma (especially β-catenin-activated)
• Aflatoxin causes a characteristic TP53 "hotspot" mutation at codon 249 (Arg→Ser)

Gross Morphology

1. Unifocal (usually large) mass - most common; may replace an entire lobe
2. Multifocal, widely distributed nodules of variable size
3. Diffusely infiltrative - permeates widely through liver, sometimes involving entire liver; may be mistaken for cirrhosis grossly

• Pale yellow (fatty change) or green (bile production) cut surface
• Tumours >2 cm more likely to show vascular invasion and intrahepatic metastases
• Portal vein invasion: snake-like tumour thrombus extending into portal vein → portal hypertension
• Extension into inferior vena cava and even right ventricle in advanced cases
• Satellite nodules around primary mass (intrahepatic metastases)

HCC: (A) Unifocal neoplasm replacing most of the right lobe. (B) Distorted trabeculae and pseudoacinar spaces (malformed bile canaliculi). - Robbins, Cotran & Kumar

Microscopic Morphology

• Trabecular (sinusoidal) - most common; thickened liver cell plates separated by sinusoids lined by flattened endothelial cells
• Pseudoglandular (acinar) - dilated bile canaliculi form pseudoacini; bile plugs present
• Solid/compact - sheets of cells with minimal sinusoidal stroma
• Scirrhous - prominent fibrous stroma (must be distinguished from cholangiocarcinoma)

• HepPar-1 (hepatocyte paraffin antigen 1) - most specific hepatocellular marker
• Glypican-3 (GPC3) - sensitive for HCC, especially well-differentiated
• AFP - in tumour cells (correlates with serum levels)
• Arginase-1 - highly sensitive and specific
• Polyclonal CEA - canalicular/bile canalicular pattern (pCEA)

The Fibrolamellar Variant

• Affects adolescents and young adults (median age 25 years)
• No preexisting liver disease or cirrhosis
• No elevated AFP
• Better prognosis than conventional HCC (up to 40% survive 10 years)
• Molecular hallmark: DNAJB1::PRKACA fusion gene → excessive protein kinase A activity

1. Large polygonal cells with abundant granular eosinophilic cytoplasm (due to abundant mitochondria - oncocytic change)
2. Vesicular nuclei with a single prominent nucleolus
3. Parallel lamellae of dense collagen (lamellar fibrosis) separating tumour cells

Fibrolamellar carcinoma: (A) Well-demarcated nodule. (B) Large eosinophilic cells with prominent nucleoli separated by lamellated collagen bands. - Robbins, Cotran & Kumar

V. COMPARATIVE SUMMARY TABLE

VI. CLINICAL FEATURES OF HCC

• Symptoms: Upper abdominal pain, malaise, fatigue, weight loss, awareness of abdominal mass
• Jaundice and ascites: Due to underlying cirrhosis or portal vein invasion
• Haemoperitoneum: From spontaneous rupture (especially in sub-Saharan Africa)
• Paraneoplastic syndromes: Hypoglycaemia (insulin-like activity), erythrocytosis (ectopic EPO), hypercalcaemia, hypercholesterolaemia

Laboratory Findings

• Serum AFP elevated in ~50% of advanced HCC; not sensitive for early disease; not elevated in fibrolamellar variant
• AST, ALT, ALP: May be elevated or normal (HCC can arise in relatively preserved liver)
• LDH: Often elevated

Imaging Hallmark

• Contrast-enhanced CT/MRI: Arterial phase enhancement followed by rapid venous washout - pathognomonic of HCC (reflects high arterialization)
• LI-RADS scoring system used for standardised radiological reporting

Prognosis and Treatment

• Surgical resection (curative; requires adequate liver reserve)
• Liver transplantation (Milan criteria: single tumour ≤5 cm or ≤3 tumours each ≤3 cm; no vascular invasion)
• Radiofrequency ablation / microwave ablation / ethanol injection (unresectable small tumours)
• Transarterial chemoembolisation (TACE) - exploits HCC arterialization
• Sorafenib (kinase inhibitor) - palliative; prolongs survival in advanced disease
• Immune checkpoint inhibitors (atezolizumab + bevacizumab) - current first-line systemic therapy

1. Cachexia
2. GI/variceal haemorrhage
3. Liver failure / hepatic coma
4. Tumour rupture with haemoperitoneum (less common)

• Nodular spectrum overview table - all stages from regenerative nodule → HCC
• Regenerative nodules - cirrhotic nodules, large cell change, small cell change
• FNH - pathogenesis, gross/micro morphology, distinguishing features
• Hepatocellular Adenoma - 4 molecular subtypes with risk stratification table
• Dysplastic nodules - LGDN vs HGDN comparison table; nodule-in-nodule concept
• HCC - epidemiology, risk factors, molecular biology, gross/micro morphology, growth patterns, IHC markers
• Fibrolamellar variant - full characterisation table
• Clinical features, lab findings, imaging hallmark, prognosis, treatment tables
• Master comparative table spanning all nodule types side-by-side